Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Craneware plc (CRWRF)
Edinburgh, GB
Craneware plc, alongside its various subsidiaries, is dedicated to developing, licensing, and providing ongoing support for specialized software solutions within the United States healthcare industry. The company's comprehensive suite of products addresses a wide range of operational and financial needs. For revenue cycle and financial management, Craneware offers Trisus pricing transparency software, designed to clarify pricing information, along with Trisus Pricing Analyzer to automate and simplify price modeling. Its Trisus Chargemaster provides automated management of chargemaster data, while InSight Audit assists government and commercial payors with audit processes. Additionally, InSight Denials facilitates the analysis, tracking, and reporting of claims denial data, and Trisus Claims Informatics offers retrospective analytical insights to identify charge capture risks. In the realm of clinical operations and supply chain, solutions include InSight Medical Necessity, which helps U.S. payors determine medical necessity; Trisus Supply, aimed at enhancing reimbursement for medical supplies; and Trisus Healthcare Intelligence, delivering patient-level insights into resource consumption. The portfolio also extends to Trisus Medication Analytic and Trisus Supplies Assistant solutions. Craneware also features a specialized line of pharmacy and drug tracking software. This includes Sentinel for drug tracking, Sentrex (a SaaS platform enabling covered entities to expand medication access), Sentrex 330, a Referral Verification System, and Sentry Core, which streamlines the complexities of pharmacy procurement, utilization, and compliance. Beyond its software offerings, Craneware provides professional and appeal services. The company was founded in 1999 and is headquartered in Edinburgh, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -24.54% | -7.98% | -11.42% | +29.07% | -28.82% | +124.07% | +414.89% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Healthcare Information Services: +14.2%+8.7% Q4'25: +14.8% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+66.7% ★ Q4'25: +133.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+15.6% Q4'25: +6.8% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+12.3% ★ Q4'25: +13.5% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%+6.6% ★ Q4'25: +13.7% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+0.9% Q4'25: +1.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.82× Q4'25: 0.21× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 6 Rev. Ana. 1 EPS Ana. |
Jun 2027 6 Rev. Ana. 1 EPS Ana. |
Jun 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
44.82M
est: 45.75M (-2.0%)
|
44.98M
est: 49.80M (-9.7%)
|
59.21M
est: 57.90M (+2.3%)
|
65.81M
est: 66.99M (-1.8%)
|
70.21M
est: 71.14M (-1.3%)
|
70.16M
est: 71.31M (-1.6%)
|
75.58M
est: 75.25M (+0.4%)
|
165.54M
est: 165.33M (+0.1%)
|
174.02M
est: 173.57M (+0.3%)
|
189.27M
est: 186.68M (+1.4%)
|
205.66M
est: 205.70M (0.0%)
|
226.09M
225.51M – 226.74M
+9.9% YoY
|
247.86M
244.67M – 250.00M
+9.6% YoY
|
269.58M
267.44M – 271.17M
+8.8% YoY
|
| EBITDA |
13.37M
est: 11.92M (+12.2%)
|
15.18M
est: 12.97M (+17.1%)
|
17.31M
est: 15.08M (+14.8%)
|
19.50M
est: 17.45M (+11.8%)
|
21.49M
est: 18.53M (+15.9%)
|
23.61M
est: 18.58M (+27.1%)
|
18.98M
est: 19.60M (-3.2%)
|
43.53M
est: 43.07M (+1.1%)
|
54.46M
est: 45.21M (+20.5%)
|
54.26M
est: 48.62M (+11.6%)
|
38.80M
est: 53.58M (-27.6%)
|
58.89M
58.74M – 59.06M
+9.9% YoY
|
64.56M
63.73M – 65.12M
+9.6% YoY
|
70.22M
69.66M – 70.63M
+8.8% YoY
|
| EBIT |
12.57M
est: 5.77M (+117.7%)
|
12.56M
est: 6.28M (+100.0%)
|
16.50M
est: 7.31M (+125.8%)
|
18.58M
est: 8.45M (+119.8%)
|
18.02M
est: 8.98M (+100.7%)
|
19.04M
est: 9.00M (+111.5%)
|
13.60M
est: 9.50M (+43.2%)
|
16.60M
est: 20.86M (-20.4%)
|
20.52M
est: 21.90M (-6.3%)
|
20.88M
est: 23.56M (-11.4%)
|
25.35M
est: 25.96M (-2.3%)
|
28.53M
28.46M – 28.61M
+9.9% YoY
|
31.28M
30.87M – 31.55M
+9.6% YoY
|
34.02M
33.75M – 34.22M
+8.8% YoY
|
| Net Income |
9.39M
est: 12.65M (-25.8%)
|
9.54M
est: 14.47M (-34.1%)
|
13.86M
est: 16.61M (-16.6%)
|
15.50M
est: 19.59M (-20.9%)
|
14.74M
est: 23.63M (-37.6%)
|
16.84M
est: 22.00M (-23.5%)
|
12.91M
est: 23.65M (-45.4%)
|
9.41M
est: 30.28M (-68.9%)
|
9.23M
est: 29.62M (-68.8%)
|
11.70M
est: 32.67M (-64.2%)
|
19.66M
est: 37.98M (-48.2%)
|
43.38M
42.93M – 43.71M
+14.2% YoY
|
48.26M
47.76M – 48.62M
+11.2% YoY
|
52.71M
52.17M – 53.12M
+9.2% YoY
|
| SGA |
13.15M
est: 17.55M (-25.0%)
|
13.97M
est: 19.10M (-26.8%)
|
16.54M
est: 22.21M (-25.5%)
|
29.07M
est: 25.69M (+13.2%)
|
18.45M
est: 27.29M (-32.4%)
|
17.19M
est: 27.35M (-37.2%)
|
15.92M
est: 28.86M (-44.8%)
|
35.65M
est: 63.41M (-43.8%)
|
129.30M
est: 66.57M (+94.2%)
|
—
est: 71.60M (-100.0%)
|
153.98M
est: 78.90M (+95.2%)
|
86.72M
86.50M – 86.96M
+9.9% YoY
|
95.07M
93.84M – 95.89M
+9.6% YoY
|
103.40M
102.58M – 104.01M
+8.8% YoY
|
| EPS |
0.35
est: 0.36 (-1.5%)
|
0.36
est: 0.41 (-11.5%)
|
0.51
est: 0.47 (+9.3%)
|
0.58
est: 0.55 (+5.4%)
|
0.55
est: 0.66 (-17.1%)
|
0.62
est: 0.62 (+0.3%)
|
0.48
est: 0.66 (-27.7%)
|
0.27
est: 0.85 (-68.3%)
|
0.26
est: 0.83 (-68.8%)
|
0.34
est: 0.92 (-63.0%)
|
0.56
est: 1.07 (-47.5%)
|
1.22
1.21 – 1.23
+14.2% YoY
|
1.36
1.34 – 1.37
+11.2% YoY
|
1.48
1.47 – 1.49
+9.2% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Keith Neilson | Co-Founder, Chief Executive Officer & Executive Director | 809.1K | male |
| Craig Thomas Preston | Chief Financial Officer, Company Secretary & Executive Director | 636.4K | male |
| Isabel Urquhart | Chief People Officer & Director | 425.0K | female |
| Ian Armstrong | Chief Growth Officer | — | male |
| Jill Goldsmith | Company Secretary | — | — |
| Lidia A. Rodriguez-Hupp | Chief Customer Officer | — | female |
| Abhilesh Gandhi | Group Chief Technology Officer | — | male |
| Tara Hanuscak | Chief Transformation Officer | — | female |
| Derek William Paterson | Chief Information Officer | — | male |
| Eric Carter | Chief Legal Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRWRF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
